2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer

被引：7
作者：
So, Alan, I [1 ]
Chi, Kim [2 ]
Danielson, Brita [3 ]
Fleshner, Neil E. [4 ]
Kinnaird, Adam [5 ]
Kapoor, Anil [6 ]
Niazi, Tamim [7 ]
Pouliot, Frederic [8 ]
Rendon, Ricardo A. [9 ]
Shayegan, Bobby [6 ]
Sridhar, Srikala S. [10 ]
Vigneault, Eric [11 ]
Saad, Fred [12 ]
机构：
[1] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada
[2] BC Canc, Vancouver, BC, Canada
[3] Univ Alberta, Dept Oncol, Div Radiat Oncol, Edmonton, AB, Canada
[4] Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada
[5] Univ Alberta, Dept Surg, Div Urol, Edmonton, AB, Canada
[6] McMaster Univ, Dept Surg, Div Urol, Hamilton, ON, Canada
[7] McGill Univ, Dept Oncol, Div Radiat Oncol, Montreal, PQ, Canada
[8] Univ Laval, Dept Surg, Div Urol, Quebec City, PQ, Canada
[9] Dalhousie Univ, Dept Urol, Halifax, NS, Canada
[10] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada
[11] Univ Laval, CHUQ, Dept Radiat Oncol, Quebec City, PQ, Canada
[12] Univ Montreal, Dept Surg, Div Urol, Montreal, PQ, Canada
来源：
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2022年 / 16卷 / 12期
关键词：
ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; INCREASED SURVIVAL; ZOLEDRONIC ACID; PLUS PREDNISONE; BONE LOSS; MEN; ENZALUTAMIDE; DOCETAXEL; ABIRATERONE;
D O I：
10.5489/cuaj.8148
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E581 / E589
页数：9
相关论文
共 47 条
  • [1] The Placenta Harbors a Unique Microbiome
    Aagaard, Kjersti
    Ma, Jun
    Antony, Kathleen M.
    Ganu, Radhika
    Petrosino, Joseph
    Versalovic, James
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (237)
  • [2] [Anonymous], 2002, Cochrane Database Syst Rev
  • [3] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) plus androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.
    Armstrong, Andrew J.
    Iguchi, Taro
    Azad, Arun
    Szmulewitz, Russell Zelig
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Alcaraz, Antonio
    Alexeev, Boris
    Shore, Neal D.
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Yamada, Shunsuke
    Haas, Gabriel P.
    Stenzl, Arnulf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
    Armstrong, Andrew J.
    Shore, Neal D.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    [J]. JOURNAL OF UROLOGY, 2021, 205 (05) : 1361 - 1370
  • [5] Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women
    Bai, Hua
    Jing, Danqing
    Guo, Aitao
    Yin, Shinan
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2013, 41 (03) : 697 - 704
  • [6] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [7] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
    Bone, Henry G.
    Wagman, Rachel B.
    Brandi, Maria L.
    Brown, Jacques P.
    Chapurlat, Roland
    Cummings, Steven R.
    Czerwinski, Edward
    Fahrleitner-Pammer, Astrid
    Kendler, David L.
    Lippuner, Kurt
    Reginster, Jean-Yves
    Roux, Christian
    Malouf, Jorge
    Bradley, Michelle N.
    Daizadeh, Nadia S.
    Wang, Andrea
    Dakin, Paula
    Pannacciulli, Nicola
    Dempster, David W.
    Papapoulos, Socrates
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) : 513 - 523
  • [8] Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients
    Bubendorf, L
    Schöpfer, A
    Wagner, U
    Sauter, G
    Moch, H
    Willi, N
    Gasser, TC
    Mihatsch, MJ
    [J]. HUMAN PATHOLOGY, 2000, 31 (05) : 578 - 583
  • [9] Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
    Burdett, Sarah
    Boeve, Liselotte M.
    Ingleby, Fiona C.
    Fisher, David J.
    Rydzewska, Larysa H.
    Vale, Claire L.
    van Andel, George
    Clarke, Noel W.
    Hulshof, Maarten C.
    James, Nicholas D.
    Parker, Christopher C.
    Parmar, Mahesh K.
    Sweeney, Christopher J.
    Sydes, Matthew R.
    Tombal, Bertrand
    Verhagen, Paul C.
    Tierney, Jayne F.
    [J]. EUROPEAN UROLOGY, 2019, 76 (01) : 115 - 124
  • [10] Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
    Chi, Kim N.
    Chowdhury, Simon
    Bjartell, Anders
    Byung Ha Chung
    Gomes, Andrea J. Pereira de Santana
    Given, Robert
    Juarez, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Brookman-May, Sabine
    Mundle, Suneel D.
    McCarthy, Sharon A.
    Larsen, Julie S.
    Sun, Weili
    Bevans, Katherine B.
    Zhang, Ke
    Bandyopadhyay, Nibedita
    Agarwal, Neeraj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (20) : 2294 - +
12345